Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial

被引：0

作者：

Bond, David A. ^{[1
]}

Huang, Ying ^{[2
]}

Reneau, John C. ^{[3
]}

Sawalha, Yazeed ^{[1
]}

Brammer, Jonathan E. ^{[1
]}

Voorhees, Timothy ^{[1
]}

Epperla, Narendranath ^{[4
]}

Sigmund, Audrey M. ^{[1
]}

Alinari, Lapo ^{[5
]}

Hanel, Walter ^{[6
]}

Gilmore, Anna ^{[7
]}

Fleming, Misty ^{[7
]}

Stamper, Kathleen ^{[7
]}

Baiocchi, Robert ^{[5
]}

Christian, Beth ^{[1
]}

Maddocks, Kami J. ^{[8
,9
]}

机构：

[1] Ohio State Univ, Div Hematol, Columbus, OH USA

[2] Ohio State Univ, Wexner Med Ctr, Dept Stat, Div Hematol, Columbus, OH USA

[3] Ohio State Univ, Wexner Med Ctr, James Canc Ctr, Columbus, OH USA

[4] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[5] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH USA

[6] Ohio State Univ, Wexner Med Ctr, James Canc Ctr, Columbus, OH USA

[7] Ohio State Univ, James Canc Ctr, Columbus, OH USA

[8] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[9] Ohio State Univ, James Canc Ctr, Columbus, OH USA

来源：

关键词：

D O I：

10.1182/blood-2024-194545

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1719 / 1720

页数：2